Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2023
   Pooled it
2. Emerging Trimethoprim-Sulfamethoxazole Resistance Among Pathogens Isolated From Diabetic Foot Ulcers: A Case Emphasizing Early Culture-Guided Therapy.Cureus · 2025
   Article
3. Clinical presentation, treatment, and antimicrobial susceptibility of 155 sequentialMicrobiology spectrum · 2025
   Article
4. Ceftobiprole activity against multidrug-resistantAntimicrobial agents and chemotherapy · 2025
   Article
5. Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study.Drugs - real world outcomes · 2024
   Article
6. Resistance to antibacterial antifolates in multidrug-resistant Staphylococcus aureus: prevalence estimates and genetic basis.The Journal of antimicrobial chemotherapy · 2023
   Article
7. Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).Antimicrobial agents and chemotherapy · 2022
   Article
8. Predominance of t355/ST152/SCCmec V clonal type among PVL-positive MRSA isolates in a tertiary care hospital in Belgrade, Serbia.PloS one · 2022
   Article
9. The Risk of Emerging Resistance to Trimethoprim/Sulfamethoxazole inInfection and drug resistance · 2022
   Article
10. Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline.Pharmacotherapy · 2021
    Review
11. Genomic Update of Phenotypic Prediction Rule for Methicillin-Resistant Staphylococcus aureus (MRSA) USA300 Discloses Jail Transmission Networks with Increased Resistance.Microbiology spectrum · 2021
    Article
12. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.CPT: pharmacometrics & systems pharmacology · 2021
    Article
13. ComparativeAntimicrobial agents and chemotherapy · 2020
    Article
14. Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.JAMA ophthalmology · 2020
    Article
15. Clinical medicine & research · 2019
    Article
16. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.Antimicrobial agents and chemotherapy · 2019
    Article
17. Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2019
    Article
18. Twenty-Year Trends in Antimicrobial Susceptibilities AmongOpen forum infectious diseases · 2019
    Article
19. Antimicrobial Resistance Surveillance and New Drug Development.Open forum infectious diseases · 2019
    Article
20. Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as